| Manufacturer | Novo Nordisk | Eli Lilly and Company |
| Pricing | Manufacturer self-pay offers: - Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
- Standard Injection Offers: Approximately $349–$499/month, depending on dose and eligibility.
- Oral Formulation: Self-pay offers starting at $149/month.
Retail prices may be higher. | Manufacturer pricing and savings: - Self-Pay Options: Starting at $499/month through eligible LillyDirect purchasing options.
- Manufacturer List Price: Approximately $1,112 for a 28-day supply before discounts or insurance.
- Savings Eligibility: Discounts depend on insurance status, approved use, and program requirements.
Actual pharmacy prices may vary. |
| Insurance Coverage | - Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for medically eligible beneficiaries.
- Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
| - Commercial Insurance: Many plans cover Mounjaro for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for eligible beneficiaries with qualifying medical indications.
- Prior Authorization: Insurers may require a type 2 diabetes diagnosis and supporting medical documentation.
- Weight Loss Alone: Generally not covered because Mounjaro is not approved specifically for weight management.
|
| Main Purpose | Improve blood sugar control in adults with type 2 diabetes. | Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. |
| Secondary Purposes | - Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes.
- Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
| - Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk.
- Weight Reduction: May produce substantial weight loss as an additional treatment effect, although weight management is not an approved Mounjaro indication.
|
| Active Ingredient | Semaglutide, a GLP-1 receptor agonist. | Tirzepatide, a dual GIP and GLP-1 receptor agonist. |
| Benefits | - Blood Sugar Control: Lowers blood glucose and HbA1c.
- Weight Management: May promote weight loss.
- Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
- Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
| - Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
- Weight Loss: Can produce clinically meaningful weight reduction in patients with type 2 diabetes.
- Appetite Regulation: Helps reduce hunger and food intake.
- Cardiovascular Health: Reduces major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
|
| Potential Health Risks | - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Possible worsening of diabetic retinopathy.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
| - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Diabetic retinopathy requires appropriate monitoring.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential | Can produce clinically meaningful weight loss in adults with type 2 diabetes, depending on dose, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. | In the SURPASS-2 trial involving adults with type 2 diabetes, Mounjaro produced approximately 7.6–11.2 kg (17–25 lb) of average weight loss over 40 weeks, depending on dose, compared with approximately 5.7 kg (13 lb) for semaglutide 1 mg. Mounjaro is not approved specifically for weight loss. |
| Administration | - Injection: Subcutaneous injection once weekly.
- Oral Tablet: Once-daily oral formulation with specific administration instructions.
| - Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Prefilled injection pens, including available multidose pen presentations.
|
| Dosing Considerations | - Starting Injection Dose: Typically 0.25 mg weekly.
- Dose Escalation: Gradual increases based on treatment response and tolerability.
- Oral Dosing: Follows a separate daily dosing schedule.
| - Starting Dose: Typically 2.5 mg weekly.
- Dose Escalation: Gradual increases in 2.5 mg increments according to the prescribing schedule and tolerability.
- Maximum Adult Dose: 15 mg once weekly.
|
| Who May Benefit Most? | Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications. | Patients aged 10 years and older with type 2 diabetes who need improved blood sugar control, including adults who may benefit from greater HbA1c reduction or additional weight loss. Adults at high cardiovascular risk may also benefit from its approved cardiovascular indication. |
| How Fast Does It Work? | - Blood Sugar: Improvements may begin within the first weeks.
- HbA1c: Reductions are generally assessed over approximately 3 months.
- Weight Loss: Typically develops gradually over several months.
| - Blood Sugar: Improvements may begin within the first weeks of treatment.
- HbA1c: Meaningful reductions generally develop over several weeks to months, with major trials assessing outcomes at 40–52 weeks.
- Weight Loss: May begin within several weeks and continue over subsequent months.
|
| Potential Side Effects | - Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
| - Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
- Other Effects: Decreased appetite and possible injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
|